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ABSTRACT 
Monocarboxylate transporters (MCTs) are vital for intracellular pH homeostasis by 
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extruding lactate from highly glycolytic cells. These molecules are key players of the 
metabolic reprogramming of cancer cells, and evidence indicates a potential 
contribution in urothelial bladder cancer (UBC) aggressiveness and chemoresistance. 
However, the specific role of MCTs in the metabolic compartmentalization within 
bladder tumours, namely their preponderance on the tumour stroma, remains to be 
elucidated.  Thus, we evaluated the immunoexpression of MCTs in the different 
compartments of UBC tissue samples (n=111), assessing the correlations among them 
and with the clinical and prognostic parameters. A significant decrease in positivity for 
MCT1 and MCT4 occurred from normoxic towards hypoxic regions. Significant 
associations were found between the expression of MCT4 in hypoxic tumour cells and 
in the tumour stroma. MCT1 staining in normoxic tumour areas, and MCT4 staining in 
hypoxic regions, in the tumour stroma and in the blood vessels were significantly 
associated with UBC aggressiveness. MCT4 concomitant positivity in hypoxic tumour 
cells and in the tumour stroma, as well as positivity in each of these regions 
concomitant with MCT1 positivity in normoxic tumour cells, was significantly 
associated with an unfavourable clinicopathological profile, and predicted lower 
overall survival rates among patients receiving platinum-based chemotherapy. Our 
results point to the existence of a multi-compartment metabolic model in UBC, 
providing evidence of a metabolic coupling between catabolic stromal and cancer cells’ 
compartments, and the anabolic cancer cells. It is urgent to further explore the 
involvement of this metabolic coupling in UBC progression and chemoresistance. 
Keywords 
Chemoresistance; monocarboxylate transporters; metabolic compartments; tumour 
stroma, urothelial bladder cancer  
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Abbreviations 
ABC ATP-binding cassette 
AJCC American Joint Committee on Cancer 
CAFs cancer-associated fibroblasts 
CAIX carbonic anhydrase IX; Cav-1, caveolin-1 
CIS carcinoma in situ; DFS, disease-free survival 
ECs endothelial cells 
FDG-PET fluoro-deoxy-glucose positron emission tomography 
HIF hypoxia-inducible factor 
MCTs monocarboxylate transporters 
MI muscle invasive 
NFB (nuclear factor kappa-light-chain-enhancer of activated B cells) 
NMI non-muscle invasive 
OS overall survival 
PFKFB3 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 
RC radical cystectomy 
SPSS Statistical Package for Social Sciences 
TOMM20 translocase of outer mitochondrial membrane 20 
TUR transurethral resection 
UBC urothelial bladder carcinoma 
WHO World Health Organization. 
INTRODUCTION 
 Bladder cancer, of which urothelial bladder carcinoma (UBC) represents 90% of all 
diagnosed cases 1, is the ninth most common cancer worldwide 2 and the costliest 
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cancer to treat from patient’s diagnosis to death 3. Its variable natural history and 
clinical behaviour, recently dissected by gene-expression profiling studies 4, endorse 
major concerns in the care of UBC patients, and embody a substantial economic 
burden in health care systems.  In fact, the group of low grade non-muscle invasive 
(NMI) UBC patients suffers from high recurrence rates. Moreover, occurrence of 
progression in the group of high grade NMI UBC is a frequent event. Additionally, 
inherent or acquired chemo-refractoriness occurs in half of the patients with muscle-
invasive (MI) disseminated disease 1, 5-7. Hence, the undeniable diagnostic and 
prognostic value of the conventional clinicopathological parameters 8 would certainly 
be refined if standardized prognostic and predictive biomarkers are included in the 
pathology reports. 
 Reprogramming of the cellular energetics, with adoption of the Warburg effect, 
has been recently included in the hallmarks of cancer 9. Increased glucose metabolism 
10, 11 and lactate production 12 was associated with a dismal outcome for bladder 
cancer patients, corroborating the use of FDG-PET (fluoro-deoxy-glucose positron 
emission tomography) scan as an efficient diagnostic tool 13, 14. Despite this, the 
preponderance of monocarboxylate transporters (MCTs), the gateways for the efflux 
of lactate from highly glycolytic cells, has just begun to be unravelled in the setting of 
bladder cancer.  
 MCTs belong to the SLC16 gene family and comprise fourteen members. The 
membrane-bound proton-coupled isoforms MCT1 and MCT4 are the best 
characterized MCTs in human tissue; they transport monocarboxylates, namely 
lactate, through the plasma membrane, with MCT1 having an ubiquitous distribution, 
and MCT4 being present in highly glycolytic tissues 15. For their proper expression at 
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the plasma membrane, MCTs require association with the cell surface glycoprotein 
CD147 16. Hypoxia seems to be a main trigger mechanism of the hyper-glycolytic 
phenotype, leading to the upregulation of pH regulators, such as carbonic anhydrase IX 
(CAIX) and MCTs, to assure intracellular pH balance 17, 18. MCTs overexpression has 
been described in several malignant contexts, associating with poor clinicopathological 
and survival parameters (reviewed in 19). Two recent studies encompassing UBC 
patients demonstrated that MCT1, MCT4 and CD147 upregulation in tumour tissue 
was significantly associated with a highly aggressive clinicopathological profile and low 
survival rates 20, 21. MCT1 and MCT4 overexpressions were identified as independent 
prognostic factors in the study by Choi et al. 21. Afonso et al. showed that a 
MCT1/CD147 double positive profile discriminated a poor prognosis group within 
patients receiving platinum-based chemotherapy, further demonstrating the 
preponderance of MCTs and CD147 interaction in promoting UBC chemoresistance in 
vitro 20.  These results anticipate a major role of the glycolytic phenotype and the 
consequent microenvironmental acidosis, which support growth, migration, invasion 
and chemoresistance abilities of urothelial malignant cells. 
 The classical view of cancer metabolism is a homogeneous glycolytic metabolism 
of the rapidly proliferating malignant cells 22. However, a tumour “ecosystem” of 
malignant cells and the surrounding stroma exists 23, and recent evidence indicates the 
occurrence of a metabolic compartmentalization and heterogeneity within the tumour 
microenvironment, not only between malignant cells’ populations, but also when 
considering the tumour stroma 24. Although a metabolic coupling between cancer cells 
and cancer-associated cells has been described in tumours like breast 25, head and 
neck 26 and prostate 27, this field remains elusive in the setting of bladder cancer. 
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 In order to explore the existence of a metabolic compartmentalization within 
bladder tumours, we aimed to evaluate, in 111 UBC patients, the immunoexpression of 
MCT1, MCT4 and CAIX in the different compartments of UBC tissue samples – 
normoxic and hypoxic tumour regions, tumour stroma and blood vessels – assessing 
the correlations among them and with the clinicopathological and prognostic 
parameters. 
RESULTS 
Clinicopathological Parameters 
 Occurrence of lymphovascular invasion and/or loco-regional metastases was 
preponderant in pT3/pT4 (p<0.001) and poorly differentiated (p=0.004 and p<0.001, 
respectively) cases. The 5-year disease-free survival (DFS) and overall survival (OS) 
rates were significantly influenced by T stage (p<0.001), grade of differentiation and 
type of lesion (p<0.001), occurrence of lymphovascular invasion (p=0.002 and p<0.001, 
respectively) and occurrence of loco-regional metastasis (p=0.002 and p<0.001, 
respectively) (data not shown). 
Biological Parameters – Immunoexpression and Associations 
 MCT1 and MCT4 were expressed in normoxic tumour regions of 35.1% (n=39) and 
64.9% (n=72) UBC tissue samples, respectively. A significant decrease was noted 
towards positivity in hypoxic areas: only 9.0% (n=10) and 24.3% (n=27) of the samples 
expressed MCT1 and MCT4 in those tumour regions, respectively (p<0.001) (Figure 1, 
A). None of the normoxic negative cases expressed either MCT isoforms in the hypoxic 
sections. Regarding the stromal compartment, 41.4% (n=46) and 51.4% (n=57) of the 
UBC samples were scored positive for MCT1 and MCT4, respectively (Figure 1, A). 
Immunoexpression in the blood vessels was observed in only 16 (14.6%) of the 
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samples stained for MCT1, and in 9 (10.0%) of the samples stained for MCT4 (10.0%) 
(Figure 1, A). Figure 2 depicts representative tissue sections of MI-UBC exhibiting 
positive immunoreactions for MCT1 (A, B) and MCT4 (C-E). 
 Significant associations were found regarding MCT4 expression both in the tumour 
and the stromal compartment, particularly when considering the hypoxic tumour 
regions (p<0.001) (Figure 1, B). Moreover, there was a tendency for cases with MCT1 
expression in normoxic regions of the tumour compartment to be concomitantly 
positive for MCT4 expression in hypoxic tumour regions (p=0.062) (Figure 1, C) and in 
the stromal compartment (p=0.073) (Figure 1, D); when we considered MCT1 
expression in hypoxic regions, we did not observe any correlation with MCT4 
expression. Figures 2, B and 2, D depict different sections of the same tumour (we 
were not able to obtain parallel images due to histological artefacts), where MCT1 is 
expressed by normoxic tumour cells, while MCT4 is expressed by hypoxic tumour cells 
and by the tumour stroma. Significant associations were observed for MCT1 
concomitant expression in the blood vessels and in the tumour stroma (p=0.001), as 
well as for MCT4 expression (p=0.001). 
 CAIX positivity was observed in the tumour compartment irrespective of the 
normoxic (69 cases, 62.2%) and hypoxic (70 cases, 63.1%) distinction (Figure 1, A). 
However, CAIX intensity of expression in concomitant positive cases for hypoxic and 
normoxic regions was consistently increased, with a better membrane definition, from 
areas close to blood vessels to areas distant from the vasculature (an example is 
depicted in Figure 2, F). This was not observed in the immunoexpression reactions of 
the remaining biomarkers. The tumour stroma and the blood vessels were positive for 
CAIX (Figure 2, F) in 93.7% (n=104) and 92.8% (n=103) of the cases, respectively (Figure 
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1, A). No associations were observed regarding CAIX and MCTs’ expression in each of 
the considered regions. 
Biological Parameters – Clinical and Prognostic Significance 
 MCT1 immunoexpression in the tumour compartment associated with a poor 
clinicopathological profile, particularly when considering the normoxic regions of the 
tissue sections, where MCT1 positivity increased with increasing stage (p=0.017), grade 
and type of lesion (p=0.042), and occurrence of lymphovascular invasion (p=0.061) 
(Table 1). The same associations were observed regarding MCT4 immunoexpression in 
the hypoxic tumour regions, in the tumour stroma and in the blood vessels (Table 2). 
However, neither MCT1 nor MCT4 positivity in the referred regions reached statistical 
significance in predicting lower DFS or OS rates. MCT4 concomitant positivity in the 
hypoxic tumour cells and in the tumour stroma, as well as positivity in each of these 
regions concomitant with MCT1 positivity in normoxic tumour cells, was predominant 
(significant associations) in high-grade MI cases where lymphovascular invasion 
occurred (Table 3). These different conditions influenced the 5-year OS rate (near 
significant associations) among patients receiving platinum-based chemotherapy 
(n=31): patients with positive scores had a lower overall survival (Figure 3, A, B and C). 
 CAIX expression in the hypoxic tumour regions was mainly observed in high-grade 
NMI papillary and MI tissue sections (p=0.016) (Table 4). Presence of this biomarker in 
normoxic zones significantly associated with a lower 5-year DFS rate (p=0.049, Figure 
3D). 
Multivariate Analysis 
In univariate analysis, pathological stage, grade and type of lesion, lymphovascular 
invasion and loco-regional metastasis were variables reaching statistical significance 
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regarding 5-year DFS and OS rates. Moreover, CAIX expression in normoxic tumour 
regions significantly influenced 5-year DFS rate. In multivariate analysis, only 
pathological stage remained as an independent prognostic factor for 5-year DFS 
(2=21.912, p=0.003; HR 2.439, 95% CI 1.203-4.944, p=0.013) and OS (2=28.109, 
p<0.001; HR 2.897, 95% CI 1.396-6.012, p=0.004) (data were adjusted to age and 
gender). 
DISCUSSION 
In the last decade, we have been assisting a huge expansion around the concepts 
of carcinogenesis and malignant dissemination. The classical view of cancer as a 
genetic disease was updated by the emergent contribution of the tumour 
microenvironment, composed of malignant cells and recruited normal cells, to its 
metabolic remodelling 22, 23. Indeed, the “Warburg Effect”, in which tumour cells 
preferentially metabolize glucose via glycolysis to lactate under aerobic conditions 28, 
29, has been revisited to introduce new mechanisms of metabolic coupling among 
malignant cells, and between malignant cells and adjacent non-tumour cells 30. 
Sonveaux and colleagues 31, using preclinical models of lung, cervical and colorectal 
cancer, described that hypoxic tumour cells produce lactate, which is exported through 
MCT4, diffusing to aerobic tumour cells that will internalize it through MCT1, being 
oxidized for energy production. This was the first study to demonstrate that metabolic 
heterogeneity exists within malignancy, similarly to what occurs under physiological 
conditions 32, and that tumour cells are capable of opportunistically adapt to distinct 
metabolic fuels to further grow and progress. Later, Lisanti’s group proposed an 
additional model of metabolic symbiosis, which they termed “Reverse Warburg 
Effect”. Using co-culture systems, they demonstrated that cancer cells drive stromal 
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cells to reverse their metabolic phenotype via mitochondria destruction by autophagy 
and upregulation of aerobic glycolysis; lactate produced by these cancer-associated 
fibroblasts (CAFs) would be then extruded through MCT4 and captured by cancer cells 
through MCT1, where it fuels malignant proliferation 33. Indeed, fibroblasts have been 
shown to rely on aerobic glycolysis in a subset of breast 34, 35 and head and neck 26 
tumours. Presence of tumour cells is sufficient to induce “pseudo-hypoxic” cell 
signalling in CAFs via HIF-1 (hypoxia inducible factor-1alpha) stabilization and NFB 
(nuclear factor kappa-light-chain-enhancer of activated B cells) activation 36. An 
increasing number of studies has been reporting this metabolic flexibility, as well as its 
impact in patients’ prognosis, in several types of cancer, namely breast 25, 37-40, head 
and neck 26, 41, prostate 27, 42, 43, gastric 44 and lung 45 cancer, osteosarcoma 46 and 
lymphoma 47. The lactate shuttling occurring within the metabolic compartments of a 
tumour is mediated through differences in the spatial distribution of MCTs 24. In fact, 
while MCT1 preferentially transports lactate into cells, MCT4 is its main exporter 15. 
These biomarkers of metabolic compartmentalization hold promise for the clinics, and 
a better understanding of the recently described metabolic symbioses within the 
tumour ecosystem will surely impact the outcome of cancer patients.  
 Altered cellular metabolism, as for other types of cancer, is an intrinsic hallmark of 
bladder cancer progression 48.  However, UBC metabolism has been described based 
on a homogeneous approach. In the present study, we used a cohort of 111 UBC tissue 
sections previously characterized for several metabolism-related proteins according to 
the traditional homogeneous view 20. In order to assess the existence of metabolic 
heterogeneity within different compartments of UBC, we evaluated the 
immunoexpression of MCT1 and MCT4 in tumour areas close to (normoxic) and distant 
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(hypoxic) from the vasculature, in tumour stroma and in blood vessels. We observed 
that MCT4 expression in hypoxic tumour regions was significantly correlated with 
expression of the biomarker in the tumour stroma. Similar (although not significant) 
associations were obtained regarding MCT1 expression in normoxic regions 
concomitant with MCT4 expression in hypoxic regions or the tumour stroma. This 
metabolic heterogeneity within UBC microenvironment was clearly correlated with 
prognostic parameters. Thus, while non-muscle invasive tumours with no 
lymphovascular invasion were predominantly negative for MCT1 immunostaining in 
normoxic tumour regions, increasing UBC aggressiveness was coupled with increasing 
MCT4 expression in hypoxic regions and/or in the tumour stroma. Moreover, the 
concomitant expression of MCT4 in hypoxic tumour regions and in the tumour stroma, 
as well as MCT4 expression in each of these regions concomitant with MCT1 
expression in normoxic tumour regions, was significantly associated with muscle 
invasive tumours were lymphovascular invasion occurred. This “three compartment” 
metabolic profile (Figure 4) resembles the model proposed by Martinez-Outschoorn 
and colleagues 24. In this review, the authors demonstrated the existence of catabolic 
populations of cancer and stromal cells that express MCT4, similarly to what was 
observed in the UBC case depicted in Figure 2, D. In the same UBC case, MCT1 
expression was present in the anabolic populations of cancer cells that were negative 
for MCT4 expression (Figure 2, B). Correlations with parameters of cancer 
aggressiveness described here have also been described in other cancer models. In the 
study by Martins et al. 38, MCT4 expression by stromal cells was acquired in near 90% 
of invasive breast carcinomas. Pértega-Gomes et al. 27 and Andersen et al. 43 showed 
that prostate cancer samples with MCT4 overexpression in CAFs and simultaneous 
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MCT1 overexpression in epithelial cancer cells are associated with poor clinical 
outcome. MCTs differential positivity in these metabolic compartments was also 
associated with higher disease stage in head and neck cancer 26. Besides evaluation of 
the differential expression of MCTs, several studies additionally report other biomarker 
alterations that further corroborate the multi-compartment metabolic 
reprogramming. Martins et al. 38 reported loss of caveolin-1 (Cav-1) in parallel with 
MCT4 gain in the tumour stroma. Cav-1 is a scaffolding protein primarily involved in 
caveolae formation and vesicular transport. Its loss is indicative of autophagy, 
increased glycolytic metabolism and oxidative stress, and reduced oxidative 
metabolism 49. Moreover, loss of Cav-1 in CAFs induces mitochondrial biogenesis in 
epithelial cancer cells 50. Zhao et al. 44  analysed MCT4 expression together with a 
mitochondrial marker (TOMM20, translocase of outer mitochondrial membrane 20), 
describing the prognostic value of their opposite patterns of expression. It would be 
interesting to further dissect the metabolic compartments of this cohort of UBC tissues 
by exploring the expression patterns of these and other metabolism-related 
biomarkers with an improved methodological approach. Nevertheless, and despite the 
limited number of biomarkers analysed in the present study, our results support, for 
the first time (and to the best of our knowledge) the existence of a multi-compartment 
tumour metabolism in urothelial bladder cancer. Furthermore, although individual 
expression of MCT1 and MCT4 in different metabolic compartments did not impact the 
prognosis of UBC patients enrolled in the study, the three-biomarker associations 
described above distinguished the prognosis of platinum-treated patients, with the 
ones with positive scores having lower overall-survival rates (near significant 
associations are probably due to the low number of cases). It is well recognized that 
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cellular and non-cellular components of the tumoural microenvironment contribute to 
chemoresistance, being stromal-mediated metabolism an important player 51. In fact, 
high mitochondrial metabolism in malignant cells, which is induced by glycolytic 
stromal cells in several cancer models 24, associates with chemoresistance 52. Glycolytic 
CAFs were shown to induce tamoxifen resistance in breast cancer cells 53. Moreover, 
microenvironmental acidosis, mediated by lactate release by CAFs, associated with 
resistance to paclitaxel and doxorubicin in the same model 54. In the setting of UBC, 
our group has recently described a putative partnership among MCT1 and its 
chaperone CD147, in mediating chemoresistance, although the metabolic 
compartmentalization of the tumour was not considered 20. MCTs also appear to 
regulate CD147 proper membrane expression 55, and a possible cooperation among 
these biomarkers in the setting of chemoresistance has been anticipated by others 56. 
CD147, a consistently upregulated protein in cancer, acts on extracellular matrix 
degradation, migration, invasion and angiogenesis 57, and has been shown to crosstalk 
with  multiple multidrug transporters of the ABC (ATP-binding cassette) family, 
typically associated with drug resistance 58. Urothelial bladder cancer is a disease 
tagged by intrinsic or acquired resistance to platinum-based chemotherapy 5, which 
advocates further research to unravel the real contribution of the metabolic coupling 
that seems to occur in this type of malignancy, to tumour aggressiveness and 
chemoresistance. 
 In the present work, we also studied MCTs expression in endothelial cells (ECs), 
and observed MCT1 and MCT4 positivity in a few cases. Moreover, MCT4 was only 
present in ECs of high grade, muscle-invasive cases. Although it has been reported that 
tumour blood vessels are largely negative for MCTs expression 59, evidence indicates 
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that tumour ECs are very heterogeneous 60, 61, with this heterogeneity extending to a 
phenotype of metabolic plasticity 62, 63. It seems that ECs, although close to oxygenated 
blood, rely mostly on glycolysis for ATP production, rather than oxidative 
phosphorylation. De Bock et al. demonstrated that loss of PFKFB3 (6-phosphofructo-2-
kinase/fructose-2,6-biphosphatase 3), a glycolytic activator, impairs vessel formation 
and branching 64. However, ECs switch to oxidative metabolism in case of decreased 
glycolytic rates 65. The occurrence of an angiogenic switch is demanding and implicates 
metabolic adaptations. Sonveaux’s group reported that lactate released by tumour 
cells is taken up, through MCT1, by ECs, being used to stabilize and activate HIF-1 66-
68. Probably, MCTs expression in tumour ECs of our UBC cases reflects the previously 
described metabolic plasticity. Presence of MCTs in both tumour and endothelial cells 
may pave the way to the development of anticancer treatments, in which multiple 
hallmarks of tumour progression, like angiogenesis and metabolic reprogramming, can 
be targeted by a unique drug. 
 Finally, we assessed, in our UBC cohort, the tissue distribution of CAIX, a 
membrane-bound catalyst that traps extracellular acid by hydration of cell-generated 
carbon dioxide to bicarbonate and protons, controlling acidification of the tumoural 
extracellular pH under hypoxic conditions 69. We observed that, although 
homogeneously distributed through normoxic and hypoxic tumour compartments, 
intensity of membrane definition was consistently higher under hypoxic conditions, 
which denotes increased activity of this catalyst in those tumour niches, as expected. 
Moreover, CAIX positivity was mainly present in hypoxic regions of high-grade non-
muscle invasive papillary and muscle invasive tumors. Correlation of CAIX expression 
with parameters of UBC aggressiveness has also been reported by others, being 
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inclusively identified as an independent prognostic factor 70, 71. Intriguingly, plasma 
membrane expression of CAIX was also observed in normoxic tumour regions, as 
previously mentioned, which was associated with a lower 5-year disease-free survival 
rate.  In the vast majority of the cases, the tumour stroma and the blood vessels were 
also stained. Probably, these interesting results reflect ongoing metabolic adaptations 
where “pseudo-hypoxic” regions coexist with normoxic, hypoxic and necrotic fractions 
of the tumour microenvironment. In fact, it has been reported that the tumor blood 
vessels in highly metastatic malignancies are themselves exposed to hypoxia, as 
indicated by pimidazole staining, due to vessel immaturity and less pericyte coverage 
72.  
 In summary, our results on MCTs and CAIX expression in the different 
compartments of a comprehensive cohort of UBC tissue sections provide evidence that 
multiple sections with different metabolic demands coexist in the urothelial tumour 
mass. Similarly to what has been described in other types of malignancies, a metabolic 
coupling between catabolic stromal cells, catabolic cancer cells and anabolic cancer 
cells seems to be patent in UBC, and additional studies are necessary to further 
explore the therapeutic implications that may arise from this newly described 
phenotype 
PATIENTS AND METHODS 
Patients and Tissue Samples 
The present study, previously approved by the Ethics Committee of the 
Portuguese Institute of Oncology, Porto, included 111 patients with urothelial bladder 
carcinomas who underwent transurethral resection (TUR) and/or radical cystectomy 
(RC) at the institution, from January 1996 to May 2006. Representative formalin-fixed 
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paraffin-embedded surgical specimens were obtained. The predefined exclusion 
criteria were as follows: diagnosis of urothelial carcinomas with variant histology, 
squamous cell or adenocarcinomas, insufficient follow-up time and/or tumour samples 
inadequate for evaluation. The median age of the patients was 70 years (range 41-86); 
ninety-one (82.0%) were male and twenty (18%) were female.   
The guidelines of the College of American Pathologists were considered for 
surgical product examination 73. Two independent pathologists reviewed 
haematoxylin-eosin stained sections, according to standard histopathological criteria. 
The American Joint Committee on Cancer (AJCC) 74 and the World Health Organization 
(WHO) 75 classification systems were used to classify the specimens by tumour stage 
and grade of differentiation. For statistical analysis, the following parameters were 
considered: T stage (3 groups), histological grade and type of lesion (considered jointly; 
4 groups), lymphovascular invasion and loco-regional metastases (see Table 1 for 
example). 
Forty-one (36.9%) patients were submitted to TUR with curative intention; of 
these, twenty-one patients underwent RC following disease recurrence and 
progression, or when multiple carcinoma in situ (CIS) lesions were present in the 
pathological specimen. Seventy (63.1%) patients had RC as their first treatment. 
Platinum-based chemotherapy regimens were administered to thirty-one (27.9%) 
patients (neoadjuvant: 6, adjuvant: 9, palliative: 16). Mean and median follow-up were 
50.9 and 37.6 months (range 1-154), respectively. The reappearance of UBC (loco-
regional dissemination or distant metastasis) more than 3 months after TUR/RC 
defined recurrence; this occurred in seventy-three (65.8%) patients. Disease-free 
survival (DFS) was defined as the time from the TUR/RC until recurrence. Overall 
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survival (OS) was defined as the time from the TUR/RC until death by bladder cancer or 
the last clinical assessment.  
Immunohistochemistry  
Immunohistochemistry protocols were used to stain representative 4μm-thick 
UBC sections, namely the streptavidin-biotin-peroxidase complex technique 
(Ultravision Detection System Anti-polyvalent, HRP, Lab Vision Corporation) for MCT4 
and CAIX detection, and the avidin-biotin-peroxidase complex assay (VECTASTAIN Elite 
ABC Reagent, RTU, Vector Laboratories) for MCT1 detection, as previously described 20. 
The primary antibodies were obtained from Chemicon (MCT1, AB3538P), Santa Cruz 
Biotechnology (MCT4, H-90, sc-50329) and AbCam (CAIX, ab15086). The following 
dilutions and incubation periods were used: for MCT1, 1:2000, overnight; for MCT4, 
1:500, 2 hours; and for CAIX, 1:2000, 2 hours. All incubations were performed at room 
temperature. Negative controls were carried out by omitting the primary antibodies. 
Colon carcinoma and gastric carcinoma sections were used as positive controls for 
MCT1 and MCT4, and for CAIX detection, respectively. 
Evaluation of Immunohistochemistry Results 
 The immunostained tissue sections, previously evaluated for MCT1, MCT4 and 
CAIX expressions in the tumour regions by light microscopy for cytoplasmic and/or 
plasma membrane staining 20, where presently re-evaluated, by two independent 
observers, considering different compartments. Thus, the tumour regions were 
assessed in their normoxic and hypoxic areas, i.e., in areas close to and distant from 
the blood microvessels, respectively. A blood microvessel was defined as a cluster of 
endothelial cells around a patent lumen clearly separated from adjacent microvessels 
and from other connective tissue components. Blood vessels commonly do not display 
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a distorted and packaged appearance, and identification is facilitated by the presence 
of red blood cells in their lumen. Even so, doubtful cases were confirmed by the 
specific staining of blood endothelial cells with an immunohistochemical marker 
(CD31), as previously described 76. The blood vessels, as well as the cancer-associated 
stroma (mainly composed of fibroblasts and connective tissue) were also assessed for 
immunoexpression of MCT1, MCT4 and CAIX. A semi-quantitative system was used to 
grade the immunoreactions, considering the sum of percentage of immunoreactive 
cells (0, 0% of positive cells; 1, < 5% of positive cells; 2, 5-50% positive cells; score 3, 
>50% of positive cells) and the intensity of staining (0, negative; 1, weak; 2, 
intermediate; 3, strong); final scores 3 were considered positive for all of the 
biomarkers studied. Regarding the malignant cells, as plasma membrane location is a 
known necessary condition for the function of the biomarkers, only the cases with 
plasma membrane staining were considered positive.  
Statistical analysis 
The analysis of the immunohistochemistry results was conducted using the 
Statistical Package for Social Sciences (SPSS) software for Windows, version 18.0. 
Associations among biomarkers’ immunoexpression and clinicopathological 
parameters were examined for statistical significance using Pearson’s chi-square (2) 
test and Fisher’s exact test (when n<5). Kaplan-Meier curves were used to evaluate 
five-year DFS and OS rates, being the differences analysed by Log-Rank or Breslow 
tests. p values lower than 0.05 were considered significant. Multivariate analysis using 
Cox proportional hazards analysis was performed with variables that achieved 
statistical significance in the univariate analysis. 
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REFERENCES 
Table 1 – Association between MCT1 immunoexpression (plasma membrane staining) 
in different compartments of urothelial bladder cancer tissue sections (normoxic 
tumour regions, hypoxic tumour regions, tumour stroma and blood vessels), and the 
clinicopathological parameters. 
 Normoxic Hypoxic Tumour stroma Blood vessels 
Clinicopathological 
parameter 
n 
Negativ
e 
(%) 
Positiv
e 
(%) 
p 
a
 
Negativ
e (%) 
Positiv
e (%) 
p 
a
 
Negativ
e (%) 
Positiv
e (%) 
p 
a
 
Negativ
e (%) 
Positiv
e (%) 
p 
a
 
TNM 
stage 
pTa, 
pT1, 
pTis 
4
5 
36 
(80.0) 
9 
(20.0) 
0.01
7 
45 
(100.0) 
0 (0.0) 
0.02
2 
26 
(57.8) 
19 
(42.2) 
0.66
0 
40 
(88.9) 
5 
(11.1) 
0.61
7 
pT2 
1
6 
10 
(62.5) 
6 
(37.5) 
14 
(87.5) 
2 
(12.5) 
11 
(68.8) 
5 
(31.3) 
14 
(87.5) 
2 
(12.5) 
pT3, 
pT4 
5
0 
26 
(52.0) 
24 
(48.0) 
42 
(84.0) 
8 
(16.0) 
28 
(56.0) 
22 
(44.0) 
41 
(82.0) 
9 
(18.0) 
Grade 
and Type 
of Lesion 
NMIP 
UC, LG 
1
0 
9 (90.0) 
1 
(10.0) 
0.04
2 
10 
(100.0) 
0 (0.0) 
0.05
8 
5 (50.0) 
5 
(50.0) 
0.34
5 
9 (90.0) 
1 
(10.0) 
0.76
3 
NMIP 
UC, HG 
3
1 
24 
(77.4) 
7 
(22.6) 
31 
(100.0) 
0 (0.0) 17 
(54.8) 
14 
(45.2) 
27 
(87.1) 
4 
(12.9) NMI UC 
in situ 
4 3 (75.0) 1 
(25.0) 
4 
(100.0) 
0 (0.0) 4 
(100.0) 
0 (0.0) 4 
(100.0) 
0 (0.0) 
MI UC 6
6 
36 
(54.5) 
30 
(45.5) 
56 
(84.8) 
10 
(15.2) 
39 
(59.1) 
27 
(40.9) 
55 
(83.3) 
11 
(16.7) 
LVI 
Negativ
e 
7
3 
52 
(71.2) 
21 
(28.8) 
0.06
1 
68 
(93.2) 
5 (6.8) 0.30
6 
44 
(60.3) 
29 
(39.7) 
0.68
6 
64 
(87.7) 
9 
(12.3) 
0.40
4 
Positive 3
8 
20 
(52.6) 
18 
(47.4) 
33 
(86.8) 
5 
(13.2) 
21 
(55.3) 
17 
(44.7) 
31 
(81.6) 
7 
(18.4) Loco-
regional 
metastas
es 
Negativ
e 
8
4 
53 
(63.1) 
31 
(36.9) 
0.64
4 
77 
(91.7) 
7 (8.3) 0.70
3 
49 
(58.3) 
35 
(41.7) 
1.00
0 
72 
(85.7) 
12 
(14.3) 
1.00
0 Positive 2
7 
19 
(70.4) 
8 
(29.6) 
24 
(88.9) 
3 
(11.1) 
16 
(59.3) 
11 
(40.7) 
23 
(85.2) 
4 
(14.8) 
a 2 or Fisher’s exact tests. 
LG, low grade; LVI, lymphovascular invasion; HG, high grade MI, muscle invasive; NMI, non-muscle invasive; NMIP, 
non-muscle invasive papillary; UC- urothelial carcinoma. 
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Table 2 – Association between MCT4 immunoexpression (plasma membrane staining) 
in different compartments of urothelial bladder cancer tissue sections (normoxic 
tumour regions, hypoxic tumour regions, tumour stroma and blood vessels), and the 
clinicopathological parameters. 
 Normoxic Hypoxic Tumour stroma Blood vessels 
Clinicopathological 
parameter 
n Negativ
e 
(%) 
Positiv
e 
(%) 
p 
a
 Negativ
e (%) 
Positiv
e (%) 
p 
a
 Negativ
e (%) 
Positiv
e (%) 
p 
a
 Nega
tive 
(%) 
Positiv
e (%) 
p 
a
 
TNM 
stage 
pTa, 
pT1, 
pTis 
4
5 
20 
(44.4) 
25 
(55.6) 
0.23
1 
41 
(91.1) 
4 (8.9) 
0.00
4 
31 
(68.9) 
14 
(31.1) 
0.00
2 
45 
(100.
0) 
0 (0.0) 
0.02
0 
pT2 
1
6 
5 (31.3) 
11 
(68.8) 
12 
(75.0) 
4 
(25.0) 
5 (31.3) 
11 
(68.8) 
13 
(81.3
) 
3 
(18.8) 
pT3, 
pT4 
5
0 
14 
(28.0) 
36 
(72.0) 
31 
(62.0) 
19 
(38.0) 
18 
(36.0) 
32 
(64.0) 
43 
(86.0
) 
7 
(14.0) 
Grade 
and Type 
of Lesion 
NMIP 
UC, LG 
1
0 
7 (70.0) 
3 
(30.0) 
0.07
5 
10 
(100.0) 
0 (0.0) 
0.01
3 
8 (80.0) 
2 
(20.0) 
0.00
4 
10 
(100.
0) 
0 (0.0) 
0.05
8 
NMIP 
UC, HG 
3
1 
11 
(35.5) 
20 
(64.5) 
28 
(90.3) 
3 (9.7) 20 
(64.5) 
11 
(35.5) 
31 
(100.
0) 
0 (0.0) 
NMI UC 
in situ 
4 2 (50.0) 2 
(50.0) 
3 (75.0) 1 
(25.0) 
3 (75.0) 1 
(25.0) 
4 
(100.
0) 
0 (0.0) 
MI UC 6
6 
19 
(28.8) 
47 
(71.2) 
43 
(65.2) 
23 
(34.8) 
23 
(34.8) 
43 
(65.2) 
56 
(84.8
) 
10 
(15.2) 
LVI 
Negativ
e 
7
3 
30 
(41.1) 
43 
(58.9) 
0.09
4 
61 
(83.6) 
12 
(16.4) 
0.01
0 
41 
(56.2) 
32 
(43.8) 
0.04
5 
68 
(93.2
) 
5 (6.8) 0.30
6 
Positiv
e 
3
8 
9 (23.7) 29 
(76.3) 
23 
(60.5) 
15 
(39.5) 
13 
(34.2) 
25 
(65.8) 
33 
(86.8
) 
5 
(13.2) Loco-
regional 
metastas
es 
Negativ
e 
8
4 
31 
(36.9) 
53 
(63.1) 
0.64
4 
65 
(77.4) 
19 
(22.6) 
0.45
2 
43 
(51.2) 
41 
(48.8) 
0.38
3 
75 
(89.3
) 
9 
(10.7) 
0.44
6 Positiv
e 
2
7 
8 (29.6) 19 
(70.4) 
19 
(70.4) 
8 
(29.6) 
11 
(40.7) 
16 
(59.3) 
26 
(96.3
) 
1 (3.7) 
a 2 or Fisher’s exact tests. 
LG, low grade; LVI, lymphovascular invasion; HG, high grade MI, muscle invasive; NMI, non-muscle invasive; NMIP, 
non-muscle invasive papillary; UC- urothelial carcinoma. 
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Table 3 – Association between MCT4 and MCT1 immunoexpressions in urothelial 
bladder cancer tissue sections, under different conditions, and the clinicopathological 
parameters. 
 MCT4 – TH and MCT4 – TS MCT4 – TH and MCT1 – TN MCT4 – TS vs MCT1 – TN 
Clinicopathological parameter n Negative 
(%) 
Positive 
(%) 
p 
a
 Negative 
(%) 
Positive 
(%) 
p 
a
 Negative 
(%) 
Positive 
(%) 
p 
a
 
TNM stage 
pTa, pT1, pTis 45 29 (64.4) 16 (35.6) 
0.002 
34 (75.6) 11 (24.4) 
0.000 
26 (57.8) 19 (42.2) 
0.000 pT2 16 4 (25.0) 12 (75.0) 10 (62.5) 6 (37.5) 3 (18.8) 13 (81.3) 
pT3, pT4 50 16 (32.0) 34 (68.0) 15 (30.0) 35 (70.0) 11 (22.0) 39 (78.0) 
Grade and 
Type of 
Lesion 
NMIP UC, LG 10 8 (80.0) 2 (20.0) 
0.002 
9 (90.0) 1 (10.0) 
0.001 
7 (70.0) 3 (30.0) 
0.001 
NMIP UC, HG 31 18 (58.1) 13 (41.9) 23 (74.2) 8 (25.8) 17 (54.8) 14 (45.2) 
NMI UC in situ 4 3 (75.0) 1 (25.0) 2 (50.0) 2 (50.0) 2 (50.0) 2 (50.0) 
MI UC 66 20 (30.3) 46 (69.7) 25 (37.9) 41 (62.1) 14 (21.2) 52 (78.8) 
LVI 
Negative 73 38 (52.1) 35 (47.9) 
0.027 
47 (64.4) 26 (35.6) 
0.001 
33 (45.2) 40 (54.8) 
0.007 
Positive 38 11 (28.9) 27 (71.1) 12 (31.6) 26 (68.4) 7 (18.4) 31 (81.6) 
Loco-
regional 
metastases 
Negative 84 40 (47.6) 44 (52.4) 
0.266 
46 (54.8) 38 (45.2) 
0.659 
31 (36.9) 53 (63.1) 
0.820 
Positive 27 9 (33.3) 18 (66.7) 13 (48.1) 14 (51.9) 9 (33.3) 18 (66.7) 
Negative, none positive; positive, one or two positive. 
a 2 or Fisher’s exact tests. 
LG, low grade; LVI, lymphovascular invasion; HG, high grade MI, muscle invasive; NMI, non-muscle invasive; NMIP, 
non-muscle invasive papillary; TN- tumour normoxia; TH- tumour hypoxia; TS- tumour stroma; UC- urothelial 
carcinoma. 
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Table 4 – Association between CAIX immunoexpression (plasma membrane staining) in 
different compartments of urothelial bladder cancer tissue sections (normoxic tumour 
regions, hypoxic tumour regions, tumour stroma and blood vessels), and the 
clinicopathological parameters. 
 Normoxic Hypoxic Tumour stroma Blood vessels 
Clinicopathological 
parameter 
n Negativ
e 
(%) 
Positiv
e 
(%) 
p 
a
 Negativ
e (%) 
Positiv
e (%) 
p 
a
 Negativ
e (%) 
Positiv
e (%) 
p 
a
 Negativ
e (%) 
Positiv
e (%) 
p 
a
 
TNM 
stage 
pTa, 
pT1, 
pTis 
4
5 
22 
(48.9) 
23 
(51.1) 
0.07
7 
16 
(35.6) 
29 
(64.4) 
0.79
4 
3 (6.7) 
42 
(93.3) 
0.99
1 
4 (8.9) 
41 
(91.1) 
0.44
3 
pT2 
1
6 
3 (18.8) 
13 
(81.3) 
5 (31.3) 
11 
(68.8) 
1 (6.3) 
15 
(93.8) 
2 (12.5) 
14 
(87.5) 
pT3, 
pT4 
5
0 
17 
(34.0) 
33 
(66.0) 
20 
(40.0) 
30 
(60.0) 
3 (6.0) 47 
(94.0) 
2 (4.0) 48 
(96.0) 
Grade 
and Type 
of Lesion 
NMIP 
UC, LG 
1
0 
6 (60.0) 
4 
(40.0) 
0.10
0 
5 (50.0) 
5 
(50.0) 
0.01
6 
0 (0.0) 
10 
(100.0
) 0.38
4 
0 (0.0) 
10 
(100.0
) 0.37
9 
NMIP 
UC, HG 
3
1 
13 
(41.9) 
18 
(58.1) 
7 (22.6) 24 
(77.4) 
2 (6.5) 29 
(93.5) 
3 (9.7) 28 
(90.3) NMI UC 
in situ 
4 3 (75.0) 1 
(25.0) 
4 
(100.0) 
0 (0.0) 1 (25.0) 3 
(75.0) 
1 (25.0) 3 
(75.0) MI UC 6
6 
20 
(30.3) 
46 
(69.7) 
25 
(37.9) 
41 
(62.1) 
4 (6.1) 62 
(93.9) 
4 (6.1) 62 
(93.9) 
LVI 
Negativ
e 
7
3 
30 
(41.1) 
43 
(58.9) 
0.41
1 
27 
(37.0) 
46 
(63.0) 
1.00
0 
6 (8.2) 
67 
(91.8) 
0.41
9 
6 (8.2) 
67 
(91.8) 
0.71
3 
Positive 3
8 
12 
(31.6) 
26 
(68.4) 
14 
(36.8) 
24 
(63.2) 
1 (2.6) 37 
(97.4) 
2 (5.3) 36 
(94.7) Loco-
regional 
metastas
es 
Negativ
e 
8
4 
34 
(40.5) 
50 
(59.5) 
0.36
7 
30 
(35.7) 
54 
(64.3) 
0.65
3 
4 (4.8) 80 
(95.2) 
0.35
8 
5 (6.0) 79 
(94.0) 
0.40
0 Positive 2
7 
8 (29.6) 19 
(70.4) 
11 
(40.7) 
16 
(59.3) 
3 (11.1) 24 
(88.9) 
3 (11.1) 24 
(88.9) 
a 2 or Fisher’s exact tests. 
LG, low grade; LVI, lymphovascular invasion; HG, high grade MI, muscle invasive; NMI, non-muscle invasive; NMIP, 
non-muscle invasive papillary; UC- urothelial carcinoma. 
  
D
ow
nl
oa
de
d 
by
 [b
-o
n: 
Bi
bli
ote
ca
 do
 co
nh
ec
im
en
to 
on
lin
e U
M
inh
o]
 at
 06
:19
 16
 D
ec
em
be
r 2
01
5 
 24 
 
 
Figure 1 – MCT1, MCT4 and CAIX immunoexpressions (plasma membrane staining) in 
different compartments of urothelial bladder cancer tissue sections (n=111) (normoxic 
tumour regions, hypoxic tumour regions, tumour stroma and blood vessels) (A). 
Correlations between MCT1 and MCT4 immunoexpression status under different 
conditions (B, MCT4 staining in the hypoxic regions of the tumour versus MCT4 
staining in the tumour stroma; C, MCT4 staining in the hypoxic regions of the tumour 
versus MCT1 staining in the normoxic regions of the tumour; D, MCT4 staining in the 
tumour stroma versus MCT1 staining in the normoxic regions of the tumour). p values 
from 2 or Fisher’s exact tests. 
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Figure 2 – Tissue sections of muscle-invasive urothelial bladder carcinomas exhibiting 
positive immunoreactions for MCT1 (A, B), MCT4 (C-E) and CAIX (F) staining. MCT1 
expression is homogeneously distributed in A, and mostly restricted to the normoxic 
tumour regions in B. The tumour stroma and the blood vessels did not stain for MCT1 
in A and B. In B, embolus of malignant cells (MCT1 positive) invading vascular 
structures are present. MCT4 expression is intense in a hypoxic tumour region 
contiguous to a necrotic fraction (C). In D, positivity for MCT4 is observed both in the 
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hypoxic tumour fraction and in the tumour stroma; positive blood vessels are also 
present. Note that B and D represent different areas of the same tumour. A detail of 
the tumour stroma and endothelial cells positive for MCT4 staining is observed in E. 
CAIX is evenly distributed in normoxic and hypoxic tumour regions, in the tumour 
stroma and in the blood vessels in F; increasing intensity and definition of plasma 
membrane staining is observed from normoxic to hypoxic regions (original 
magnifications: A, C, E - 200X; B, D, F - 100X). 
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Figure 3 – Kaplan-Meier curves demonstrating: 5-year overall survival (A, B, and C) in 
34 platinum-treated urothelial bladder cancer patients based on MCT1 and MCT4 
immunoexpression status under different conditions (A, MCT4 staining in the hypoxic 
regions of the tumour concomitant with MCT4 staining in the tumour stroma; B, MCT4 
staining in the hypoxic regions of the tumour concomitant with MCT1 staining in the 
normoxic regions; C, MCT4 staining in the tumour stroma concomitant with MCT1 
staining in the normoxic regions of the tumour; A-C: negative, none positive / positive, 
one or two positive); 5-year disease-free survival in 111 urothelial bladder cancer 
patients based on CAIX (D) immunoexpression status. p values from Log-Rank or 
Breslow tests.  
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Figure 4 – Schematic representation of the three-compartment metabolic coupling 
occurring in urothelial bladder carcinoma. Catabolic hypoxic cancer cells and catabolic 
stromal cells express MCT4, as demonstrated by MCT4 staining (original magnification 
100X), being coupled to anabolic normoxic cancer cells that express MCT1, as 
demonstrated by MCT1 staining (original magnification 100X). Glycolysis-originating 
lactate is exported through MCT4 expressing cells, and imported through MCT1 
expressing cells, where it fuels mitochondrial respiration, driving malignant 
proliferation. This leads to a phenotype of tumour aggressiveness and 
chemoresistance [this figure was produced, in part, using Servier Medical Art 
(www.servier.com/Powerpoint-image-bank)]. 
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